SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Discussion centers on speculation that Middle East LNG disruptions and shipping risks could strengthen demand and pricing for U.S. exporters, including NextDecades Rio Grande project. Bulls point to the projects progress and future capacity, while skeptics emphasize that NEXT has no current LNG production or revenue and still faces construction, financing, and competition risks.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,546,266,383.70521. The last known price of Dogecoin is 0.07588453 USD and is up 0.89 over the last 24 hours. It is currently trading on 1543 active market(s) with $1,129,852,058.92 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention for its choppy, weak trading and repeated difficulty holding above the eight-cent area, with traders also linking pressure to broader crypto-market declines. The conversation is split between bearish frustration over losses and calls to buy the dip or hold for a recovery.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Traders are focused on Zebecs payroll and payments expansion, including MoneyGram/Stellar links and Robinhood Chain support, as potential adoption drivers. Bullish holders are accumulating, while skeptics question whether actual usage will translate into ZBCN demand given its weak, uneven price performance.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zooms Anthropic investment is drawing attention amid IPO-filing and valuation chatter, with bullish traders viewing the stake as a potential source of value. Others question whether it can offset Zooms modest core-business growth and competitive pressures; discussion also references recent earnings beats and raised full-year guidance.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPaths order for more than 50,000 optical assemblies for defense-drone cameras is drawing attention to its counter-drone and thermal-optics business. Bulls see room for recurring demand and further defense orders, while skeptics want earnings and revenue to confirm the growth story; broad market and defense-sector weakness have also weighed on the shares.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

KTOS is drawing attention for its steep, prolonged selloff and repeated tests of key support, with traders debating whether the weakness reflects valuation concerns, insider selling and a broader defense-sector pullbackor an oversold buying opportunity. Optimists point to contract wins, growth prospects and analyst upgrades, while skeptics say positive developments have not reversed the downtrend ahead of upcoming earnings.

Cosmos (ATOM) is a cryptocurrency . Cosmos has a current supply of 538,743,080.257876. The last known price of Cosmos is 1.54934617 USD and is up 3.36 over the last 24 hours. It is currently trading on 999 active market(s) with $34,414,170.84 traded over the last 24 hours. More information can be found at https://cosmos.network/.

Cosmos

Cosmos ATOM is drawing attention amid persistent price weakness, with holders highlighting staking rewards and hoping for renewed adoption and an altcoin rebound. Bearish traders counter that token inflation and a fading ecosystem are weighing on the outlook; institutional-adoption and regulatory catalysts remain largely speculative in the discussion.

Sky (SKY) is a cryptocurrency and operates on the Ethereum platform. Sky has a current supply of 23,452,431,915.60596656 with 23,422,827,962.33348843 in circulation. The last known price of Sky is 0.06706993 USD and is up 0.91 over the last 24 hours. It is currently trading on 257 active market(s) with $49,629,100.47 traded over the last 24 hours. More information can be found at https://sky.money/.

Skycoin

Galaxy Digitals adoption of Skys yield-bearing stablecoin for its treasury and lending collateral, alongside a reported purchase of SKY, is driving discussion of growing institutional interest in the Sky ecosystem. Traders are watching for a breakout, while others see the recent pullback as a warning and question whether the rally can hold.

Direxion Shares ETF Trust - Direxion Daily GOOGL Bull 2X ETF

Direxion Daily GOOGL Bull 2X Shares ETF

Alphabets sharp post-earnings selloff is driving attention to GGLL, with many traders buying the dip for a rebound while others warn that market weakness and deteriorating technicals could bring further declines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?

T expands customer benefits with complimentary LifeMD memberships, offering virtual care, prescriptions and pharmacy services.

AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD

AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMDPR NewswireDALLAS, Sept. 15, 2026 DALLAS, Sept. 15, 2026 /PRNewswire/ -- Through an exclusive...

LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates

LifeMD (LFMD) delivered earnings and revenue surprises of +20.00% and -3.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

LifeMD's Series A Preferred Stock Crosses Above 9.5% Yield Territory

In trading on Monday, shares of LifeMD Inc's 8.875% Series A Cumulative Perpetual Preferred Stock (Symbol: LFMDP) were yielding above the 9.5% mark based on its quarterly dividend (annualized to $2.2188), with shares changing hands as low as $22.91 on the day. As of last clos...

CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Hims & Hers Expands Integrated Health Access via Platform Expansion

HIMS expands its integrated telehealth ecosystem with a new weight-loss membership and a planned Eucalyptus acquisition to broaden virtual care.

Is CAH Becoming the Backbone of US Healthcare Infrastructure?

Cardinal Health is expanding beyond drug distribution into specialty care, logistics and nuclear medicine, deepening its role in US healthcare infrastructure.

Bloomberg Businessweek Daily 5/18/2026

Today, Matt Schettenhelm, Bloomberg Intelligence Senior Litigation Analyst, breaks down a California's jury's rejection of Elon Musk's claim that Sam Altman betrayed OpenAI's original mission when it...

LifeMD (NASDAQ:LFMD) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

LifeMD (NASDAQ:LFMD - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.06). LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%.The business had...

LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates

LifeMD (LFMD) delivered earnings and revenue surprises of -42.86% and +3.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

LifeMD Inc

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Hims shares logged their best session in a month and added after-hours gains.</li><li>Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims.</li><li>Hims continues to broaden its platform through international expansion and new services.</li></ul>Hims &amp; Hers Health Inc. shares posted their strongest session in a month on Monday and added another 0.7% in after-hours trading, with both trading days so far this year ending higher.The move came despite a cautious note from Citi, which said Novo Nordisk’s latest Wegovy announcement could pressure Hims’ GLP-1 business in 2026. Citi kept a 'Sell' rating on the stock with a $30 price target.<h2 class="st-heading-2">Novo’s Oral Wegovy Move Leaves HIMS On The Sidelines</h2>Novo Nordisk said on Monday that its oral Wegovy pill is now broadly available in the U.S., with pricing starting at $149 a month for specific doses and higher prices for larger doses later in 2026. Novo also said commercially insured patients could access the pill for as low as $25 per month.Citi said Hims was again left off Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx. The firm said this likely reflects disagreements between Novo and Hims around Hims’ compounded semaglutide strategy, and added that the broader rollout of Wegovy pills could put pressure on Hims’ GLP-1 business this year.<h2 class="st-heading-2">Broader Growth Drivers Remain in Focus</h2>Hims &amp; Hers Health has spent recent months expanding its platform beyond weight loss through geographic expansion, new product launches and acquisitions. In December, the company announced the expansion of its Weight Loss Program to the UK, including the official launch of the Hers platform for eligible women, offering access to weight-management care following assessments by GMC-registered doctors. The UK offering includes branded GLP-1 options and oral non-prescription treatments.Hims has also entered Canada following the completion of its acquisition of Livewell, a Canadian digital health platform. Additionally, the company said it will acquire YourBio Health, which develops capillary whole blood sampling technology, including the TAP device that uses bladeless microneedles.&nbsp;Separately, Hims launched its Labs in-depth testing experience, which provides customers with blood-based biomarker testing and doctor-developed action plans across areas such as heart health, metabolism, hormones and inflammation. The company said it plans to expand the Labs offering over time to include additional biomarker tests, at-home testing devices and advanced diagnostics.In December, Barclays initiated coverage of Hims with an ‘Overweight’ rating and a $48 price target, noting that expectations for the business had become more reasonable and pointing to the addition of other growth drivers for FY26.<h2 class="st-heading-2">Investors Look Beyond Near-Term GLP-1 Pressure</h2>Competition in the GLP-1 weight-loss space continues to broaden. Novo Nordisk and Eli Lilly dominate the market with Wegovy and Zepbound, respectively, and Lilly’s injectable Zepbound has been shown in a head-to-head study to deliver greater average weight loss than Wegovy. Novo has since launched the first FDA-approved oral GLP-1 for weight loss, while Lilly is advancing its own oral candidate, orforglipron, which is under regulatory review. Both companies have also cut cash-pay prices for lower doses as access expands beyond insurance-covered channels.Beyond Novo and Lilly, other drugmakers are developing next-generation obesity treatments, including Lilly’s retatrutide and Novo’s CagriSema, while additional companies such as Pfizer and Structure Therapeutics are working on oral weight-loss drugs.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_55bef6044e.webp" alt="hims ss.png" width="972" height="144"><figcaption>HIMS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said, “Injections vs pills for weight loss will be a big deal. Who wouldnt rather take a pill. HIMS needs to get Novo deal or somehow get access to sell the pill, otherwise their weight loss related revenue will tank”<stembedurl>https://stocktwits.com/Matril/message/640906333</stembedurl>Another user said that with GLP-1 pills now available through large retailers such as Costco, the downside risks are already reflected in the stock price, and added that future catalysts could include share buybacks and increased trading activity.<stembedurl>https://stocktwits.com/ros_/message/640880655</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 30% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Costco Wholesale Corp

CVS Health Corp

GoodRx Holdings Inc

Structure Therapeutics Inc - ADR

Hims & Hers Health Inc

Lilly(Eli) & Co

Novo Nordisk A/S

Pfizer Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$LFMD Federated Hermes bought 2.5M shares last quarter, this quarter they bought another 1.5M. Seems they believe in LFMD and is now the biggest shareholder.

rolypoly101

$LFMD under 2 this week maybe under one after earnings.  the revenue is going to be 4 times the value of the company.  wow.

jerry del guercio

$LFMD less and less people on the site or app every month.  company burning cash like mad when they stopped advertising.  they have the infrastructure all ready.  yet company still isnt profitable.  gj.

$LFMD lmao good thing he only bought $3K worth. Unfortunately that was his entire net worth 😂

$LFMD I can’t believe this is almost in the 1s again…selling this above $5 was one of the best investment decisions I’ve ever made

Love

$LFMD This is so undervalued. Market cap now 50% of annual revenue. Screaming buy right now.

Jonathan

$LFMD Nov 9th reporting, much earlier than before and also in the morning. Seems they are eager to do the report. Hope that means good news!

$LFMD gj justin.  Basically taking your stock almost into reverse split territory.  then bye bye company.

$LFMD people might actually save money on food and grocery bill paying the monthly cost for weight loss drugs. 

This might be one of the greatest marketing campaigns or ideas for LifeMD. High Inflation? Don’t fret, get Ozempic!

$LFMD very interesting watching the fall here. The guidance cut last time has been a killer. We are definitely also suffering tax loss harvesting right now. Potential remains- but will they deliver the comeback

King OfTheNorth

$LFMD  A lot of big investors and firms bought LFMD at a much higher price than the current price.  And many also ended up exiting for a loss. Thanks for the info though.

Feed

News

Sentiment

Earnings

Fundamentals

Info

LFMD LifeMD Inc

Fundamentals

Latest LFMD News